Holen Sie sich die Stockscreener-App
0.22
4.71%
0.0099
Handel nachbörslich:
.22
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors - GlobeNewswire
GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities LawsuitContact The Gross Law Firm - PR Newswire
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS – Company AnnouncementFT.com - Financial Times
GOSS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
GOSS Stockholders Have Opportunity to Lead Gossamer Bio, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. ... - Caledonian Record
GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW - GlobeNewswire
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS - PR Newswire
GOSS 10-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses Ma - The National Law Review
GOSS Investor AlertGossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - PR Newswire
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile
GOSSAMER DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Earnings call transcript: Gossamer Bio Q1 2026 sees revenue beat, EPS miss - Investing.com UK
Gossamer Bio, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GOSS) 2026-05-21 - Seeking Alpha
GOSS Investor Alert: Gossamer Bio Securities Fraud LawsuitInv - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSSAMER BIO, INC. (GOSS) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by June 1, 2026 - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Goldman Sachs Adjusts Outlook for Gossamer Bio (GOSS) - GuruFocus
Robbins LLP Reminds GOSS Investors of the Pending Class - GlobeNewswire
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2026 Earnings Call Transcript - Insider Monkey
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile
Wedbush Maintains Gossamer Bio(GOSS.US) With Hold Rating, Maintains Target Price $1 - Moomoo
GOSS Maintained by Barclays -- Price Target Lowered to $0.28 - GuruFocus
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire
The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026GOSS - Morningstar
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - Sahm
Is Gossamer Bio (GOSS) Undervalued After Q1 2026? EPS -$0.20 (mi - GuruFocus
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit - GuruFocus
Gossamer Bio (GOSS) Reports Mixed Results for PROSERA in Q1 2026 Earnings Call - GuruFocus
Key facts: Gossamer Bio voting deals; PROSERA benefit; Q1 loss $46.7M - TradingView
GOSS Stock Chart | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
GOSS Reports $99.2 Million in Cash Reserves for Future Operations - GuruFocus
Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June - RTTNews
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel ... - Caledonian Record
Latham Represents Gossamer Bio Inc in Exchange Offer and Consent Solicitation Transaction - Latham & Watkins LLP
Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval - MSN
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bi - GuruFocus
Gossamer Bio Q1 2026 Deep Dive: EPS Misses by 17.6%, Revenue Up 72% - AlphaStreet
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses M - GuruFocus
Gossamer Bio shares decline after wider-than-expected Q1 loss despite revenue beat (GOSS) - MSN
Gossamer Bio Q1 2026 Earnings Call Transcript - MarketBeat
Gossamer Bio Releases Q1 2026 Financial Results - AlphaStreet
Gossamer Bio (GOSS) Launches Exchange Offer for Convertible Notes - GuruFocus
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire
User - The Chronicle-Journal
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):